Biomerica Secures PLA Code For InFoods IBS Test, Advancing Reimbursement Access

Biomerica (BMRA) announced that its inFoods IBS test has been granted a Proprietary Laboratory Analysis (PLA) code by the American Medical Association, effective October 1, 2025. This critical development enables claims submissions to Medicare and private insurers, significantly bolstering the test's commercialization strategy by ensuring reimbursement and expanding patient access to its personalized IBS diagnostic. The news drove BMRA shares up over 6%, reflecting investor optimism regarding the test's potential to address a major unmet medical need for IBS patients.

Analysis

Biomerica, Inc. (BMRA) has achieved a critical commercialization milestone for its inFoods IBS test by securing a Proprietary Laboratory Analysis (PLA) code from the American Medical Association, set to become effective on October 1, 2025. This development is pivotal as it establishes a dedicated billing pathway, enabling reimbursement claims to Medicare and private insurers, which significantly de-risks the company's revenue model for the product. The test addresses a substantial unmet need, with Irritable Bowel Syndrome affecting 10-15% of U.S. adults and creating up to $10 billion in annual medical costs. The value proposition of the inFoods test is further substantiated by clinical trial results from a June 2025 Gastroenterology journal, which demonstrated significantly greater symptom improvement for patients on its guided diets versus placebo. The market's positive reception to this regulatory and commercial progress is reflected in the 6.1688% increase in BMRA's stock price to $3.27, signaling investor confidence in the test's future contribution to Biomerica's growth.

Key Decisions for Investors

• The PLA code approval materially de-risks the commercial pathway for the inFoods IBS test, presenting a potential long-term catalyst for investors, though significant revenue impact is not expected until after the October 2025 effective date.
• Investors should monitor the company's execution on its commercialization strategy, including securing contracts with major insurers and establishing physician adoption rates ahead of the Q4 2025 launch.
• Given the stock's immediate positive reaction, potential investors should assess whether the near-term valuation already incorporates this news and consider the timeline risk associated with the 2025 effective date.